Skip to main content
. 2022 Apr 28;59(4):2100768. doi: 10.1183/13993003.00768-2021

FIGURE 2.

FIGURE 2

Exacerbation outcome in patients with dissociated symptoms and type 2 inflammation biomarkers. a) High symptoms/low type 2 inflammation biomarkers. We observed no benefit with increased corticosteroid dose. b) Low symptoms/high type 2 inflammation biomarkers. We observed substantial benefit with increased corticosteroid dose. HR: hazard ratio.